IOBTQ (IO Biotech) DeferredTaxAndRevenue: $0.00 Mil (As of Sep. 2025)


What is IO Biotech DeferredTaxAndRevenue?

IO Biotech IOBTQ +27.50% DeferredTaxAndRevenue is $0.00 Mil as of Sep. 2025. The stock has 1 warning sign investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

IO Biotech's current deferred tax and revenue for the quarter that ended in Sep. 2025 was $0.00 Mil.

IO Biotech DeferredTaxAndRevenue Related Terms

IO Biotech DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for IO Biotech's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IO Biotech DeferredTaxAndRevenue Chart

IO Biotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
DeferredTaxAndRevenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

IO Biotech Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.00 Mil mean?
IO Biotech (IOBTQ) has a DeferredTaxAndRevenue of $0.00 Mil as of Sep. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on IO Biotech.
Is IO Biotech's DeferredTaxAndRevenue too high?
IO Biotech's current DeferredTaxAndRevenue is $0.00 Mil.
How does IO Biotech's DeferredTaxAndRevenue compare to CNBX and ENDV?
IO Biotech's DeferredTaxAndRevenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on IO Biotech. IO Biotech's current DeferredTaxAndRevenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IO Biotech stock overvalued right now?
IO Biotech (IOBTQ) has a current DeferredTaxAndRevenue of $0.00 Mil. The current DeferredTaxAndRevenue is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For IO Biotech (IOBTQ), the current DeferredTaxAndRevenue is $0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IO Biotech Business Description

Address Ole Maaloes Vej 3, Copenhagen N, DNK, DK-2200
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.